Efficacy and safety of Zhichuanling oral liquid in patients with stable asthma-COPD overlap: protocol for a multicenter, randomized, double-blind, placebo-controlled trial
Background Asthma-COPD overlap (ACO) is a heterogeneous chronic airway condition with features of both asthma and chronic obstructive pulmonary disease (COPD). Compared with either disease alone, ACO is usually associated with heavier symptoms, more exacerbations, faster lung-function decline, and poorer quality of life. Stable ACO is typically managed with inhaled corticosteroids (ICS) plus long-acting beta2-agonists (LABA) and/or long-acting muscarinic antagonists (LAMA), yet many patients still have residual cough, wheezing, sputum, and limited lung-function improvement. Zhichuanling Oral Liquid is a marketed Chinese patent medicine with pharmacological and clinical evidence for relieving wheezing and cough and improving ventilation, but data in adults with stable ACO remain limited. Objective This trial will evaluate whether add-on Zhichuanling Oral Liquid improves lung function, symptoms, and inflammation-related indicators versus placebo in patients with stable ACO receiving conventional Western medicine, and will assess its safety. The primary outcome is the change from baseline in the pre-bronchodilator percentage of predicted forced expiratory volume in 1 s after 4 weeks (Delta FEV1%pred). Methods and analysis This multicenter, prospective, randomized, double-blind, placebo-controlled trial was designed to enroll 200 patients with stable ACO at 11 Chinese centers (1:1). The protocol specifies 4 weeks of conventional Western medicine in both groups, with add-on Zhichuanling Oral Liquid (10 mL orally, three times daily) or matched placebo. Assessments are scheduled at baseline and weeks 1–4. Secondary outcomes include changes in COPD Assessment Test (CAT) score, wheezing/cough/sputum scores, FEV1, forced vital capacity (FVC), FEV1/FVC, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and blood eosinophil count. Safety will cover adverse events, vital signs, physical examination, laboratory tests, and electrocardiography. The primary outcome will be analyzed by analysis of covariance. Ethics and dissemination Ethics approval has been obtained from China-Japan Friendship Hospital (2024-KY-230-1). Written informed consent was required before enrollment. Resultswill be disseminated via peer-reviewed publications and conferences after data analysis; no outcome data have been analyzed or reported at submission. Clinical Trial Registration https://itmctr.ccebtcm.org.cn/mgt/project/view/5834415100139749447 , International Traditional Medicine Clinical Trial Registry, ITMCTR2024000587.
Authors
- Yirun Li
- Xinyi Zhang (ORCID: https://orcid.org/0000-0002-4708-3435)
- Demin Li (ORCID: https://orcid.org/0000-0002-4009-2048)
- Xuanling Zeng
Institutions
- Beijing University of Chinese Medicine (CN)
- China-Japan Friendship Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fmed.2026.1938672
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00